Table 2.
Cytotoxicity and antiviral activity in HEL[a] cell cultures.
|
Compound |
Cytotoxicity |
Antiviral EC50 [c] [μM] |
|||||
|---|---|---|---|---|---|---|---|
|
|
CC50 [b] [μM] |
HSV‐1 |
HSV‐1/TK− |
HSV‐2 |
Vaccinia |
AdV‐2 |
HCoV |
|
15 |
>100 |
54 |
39 |
2.0 |
10 |
42 |
>100 |
|
16 |
>100 |
33 |
41 |
25 |
48 |
>100 |
>100 |
|
17 |
>100 |
16 |
16 |
2.2 |
7.9 |
60 |
40 |
|
18 |
>100 |
9.8 |
19 |
14 |
17 |
>100 |
4.9 |
|
cidofovir |
>250 |
2.4 |
4.7 |
1.0 |
10 |
6.4 |
– |
|
acyclovir |
>250 |
2.4 |
146 |
0.05 |
>250 |
– |
– |
|
alovudine |
>250 |
– |
– |
– |
– |
5.9 |
– |
[a] HEL: human embryonic lung fibroblast cells. Viruses: herpes simplex virus type 1 (HSV‐1) or type 2 (HSV‐2); a thymidine‐kinase deficient (TK−) mutant of HSV‐1; vaccinia virus; human adenovirus type 2 (AdV‐2) and human coronavirus (HCoV) 229E. [b] 50 % Cytotoxic concentration based on the formazan‐based MTS cell viability assay. [c] 50 % Effective concentration, based on measuring cell viability with the MTS assay.